One of the most frustrating puzzles in multiple sclerosis biology is why the brain loses its ability to repair myelin over time, even when the immune attack partially subsides. New preclinical evidence points to a specific molecular culprit — fibronectin accumulation — and a receptor pathway in blood vessel cells that may be driving this repair failure, offering a more targeted intervention point than anything currently in the clinical toolkit.
Working in a mouse model of nonremitting experimental autoimmune encephalomyelitis, researchers identified that deleting TNFR2 — the tumor necrosis factor receptor 2 — specifically from endothelial cells, rather than globally, produces a chronic, non-resolving disease state marked by failed remyelination. In this context, fibronectin, an extracellular matrix glycoprotein, accumulates abnormally in demyelinated lesions and appears to suppress the differentiation of oligodendrocyte precursor cells into mature, myelin-producing oligodendrocytes. Critically, pharmacological inhibition of fibronectin restored remyelination in these animals, reversing what had appeared to be a structural barrier to repair.
This work sits within a growing body of literature implicating the extracellular matrix as an active inhibitor of CNS repair rather than a passive scaffold. Fibronectin has previously been flagged in MS lesion analyses as a correlate of remyelination failure, but causal mechanistic evidence in vivo has been limited. What elevates this study is the identification of endothelial TNFR2 signaling as an upstream regulator of that fibronectin accumulation — tightening the mechanistic chain considerably. The finding that global TNFR2 deletion does not recapitulate the same phenotype as endothelial-specific deletion is a meaningful refinement that has implications for how TNF-pathway therapies, which carry well-known risks in MS, might be redesigned for cell-type specificity. As a single animal study, replication in human tissue and eventual clinical translation remain significant hurdles. Still, this represents a potentially paradigm-shifting mechanistic insight rather than incremental confirmation.